Short Interest Update on Astrazeneca PLC (AZN)

Astrazeneca PLC (AZN) : Traders are increasing their bearish positions on the stock, as is visible by the 5% jump in the outstanding short positions; a total addition of 1,449,826 shares on the sell side. On Jul 29, 2016, the total short positions were 28,745,918 shares, which went up to 30,195,744 shares by the close of trading on August 15, 2016. It will take 5 days for the bears to roll over or cover. An average of 6,209,565 shares exchange hands daily. 1.2% of the float of the stock has been sold short by the bears. The short interest information was released on Wednesday Aug 24th after the market close.

Astrazeneca PLC (NYSE:AZN): The stock opened at $34.15 on Wednesday but the bulls could not build on the opening and the stock topped out at $34.51 for the day. The stock traded down to $33.42 during the day, due to lack of any buying support eventually closed down at $33.50 with a loss of -0.98% for the day. The stock had closed at $33.83 on the previous day. The total traded volume was 5,431,911 shares.


AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory, inflammation and autoimmunity, and infection, neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9), a treatment for hyperkalaemia, a condition associated with increased mortality in patients with chronic kidney disease (CKD), diabetes mellitus (DM) and chronic heart failure (CHF).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *